Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics
Regeneron Pharmaceuticals, Inc. (REGN)
Today's Latest Price: $555.24 USD
Updated Sep 18 4:00pm
Add REGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
REGN Stock Summary
- REGN has a higher market value than 96.71% of US stocks; more precisely, its current market capitalization is $59,073,312,845.
- With a year-over-year growth in debt of 211.53%, Regeneron Pharmaceuticals Inc's debt growth rate surpasses 92.72% of about US stocks.
- Over the past twelve months, REGN has reported earnings growth of 55.02%, putting it ahead of 83.77% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to Regeneron Pharmaceuticals Inc, a group of peers worth examining would be LRCX, AMD, SNPS, MU, and VRTX.
- Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to www.regeneron.com.
REGN Stock Price Chart Technical Analysis Charts
REGN Price/Volume Stats
| Current price | $555.24 | 52-week high | $664.64 |
| Prev. close | $565.00 | 52-week low | $271.37 |
| Day low | $544.96 | Volume | 1,977,113 |
| Day high | $567.83 | Avg. volume | 1,152,598 |
| 50-day MA | $609.91 | Dividend yield | N/A |
| 200-day MA | $513.44 | Market Cap | 59.07B |
Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $555.24 | $612.24 | 8% |
We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 47th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 108.12; that's higher than 95.81% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 10.83% of the free cash flow producing stocks we're observing.
- REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.6% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 6% |
| 1% | 7% |
| 2% | 8% |
| 3% | 9% |
| 4% | 10% |
| 5% | 12% |
Want more companies with a valuation profile/forecast similar to that of Regeneron Pharmaceuticals Inc? See HRC, EBS, HBIO, DXCM, and AMED.
Loading social stream, please wait...